The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

DUBLIN--(BUSINESS WIRE)--The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key ...

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Transcenta Holding-B (06628.HK) announced that it presented preclinical data at the 2026 AACR Annual Meeting highlighting its ...

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity By 2030 With The 1St Approved Bsadc By 2028 - Clinical Trials, Regulatory Approvals, Development Platforms.

The complexity of antibody-drug conjugates (ADCs) demands equally sophisticated analytical strategies. Researchers must navigate fragmented workflows, manual sample preparation, and experimental ...

Researchers use new antibody–drug conjugates that combine a CD4 mimic with neutralizing antibodies to inhibit human immunodeficiency virus (HIV) entry into host cells. New antibody–drug conjugates ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...

Activation of the cGAS-STING pathway activates the immune system through the production of type I interferons. There is knowledge that myeloid cell populations are among the most sensitive to STING ...